JV's and buyouts, yep, we will see many names pop up. Who knows, maybe a competitor?
Like a global biopharmaceutical company who trades on NasdaqGS with a $26 B market cap with a subsidiary in the stem cell field and has been stated by ACT as "one of our primary competitors in retinal disease indication"?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.